Diabetes, obesity, metabolic liver disease, cardiovascular and kidney health.
Metabolic disease is the largest noncommunicable disease burden in the world, and the one moving fastest.
Diabetes, obesity, metabolic liver disease (MASLD and MASH, formerly known as NAFLD and NASH), chronic kidney disease and cardiovascular disease are rarely separate conditions in the same person. They share mechanisms, they compound one another, and they are usually managed apart.
Metabolic medicine has advanced further in the last decade than in the three before it. New classes of therapy change the course of diabetes, obesity and kidney disease. A treatment now exists for metabolic liver disease where none did. Continuous glucose monitoring and automated insulin delivery have changed what daily life with type 1 diabetes can look like.
Yet a large proportion of the people who would benefit from these advances are never identified. Many who are identified cannot obtain or afford what exists. And where care is available, it is often organised one condition at a time, across specialties that have few practical ways to coordinate around the same patient.
A large share of people living with metabolic liver disease, early chronic kidney disease and prediabetes remain undiagnosed. We work on the pathways that identify them in time, and on preventing progression and complications in those already diagnosed.
Medicines and technology alike. Access to newer therapies, and to continuous glucose monitoring, automated insulin delivery and the diagnostics that modern metabolic care depends on.
One patient may live with type 2 diabetes, obesity, metabolic liver disease, chronic kidney disease and cardiovascular risk, and be seen by several specialists, each responsible for part of the picture. Few systems are built to hold the whole of it. We work on care organised around the continuum rather than its parts.
Building the knowledge, skills and leadership metabolic care needs, from detection in primary care through to the specialists who manage complications.
One Chair leads the stream. Profiles will be updated as appointments are confirmed.
Dr. Banshi Saboo is a distinguished healthcare leader with a relentless commitment to advancing diabetes care and endocrinology. With a proven track record of leadership and innovation, he has spearheaded impactful initiatives that have garnered recognition both nationally and internationally. Notably, he launched the groundbreaking “Diabetes-Free India: 2030” project, acknowledged by the Hon’ble President of India, Shri Pranab Mukherjee. As the Founder of NGO Diabetes Care India and the Indian Sweet Registry Project, he continues to drive transformative change in diabetes management and awareness.
Read full profile →Projects will be added here when approved and confirmed.
Verified publications, reports, evidence reviews and implementation resources will appear here as they become available.
Conference abstracts from stream work
To be addedScientific posters presented at congresses
To be addedPeer-reviewed publications
To be addedTalks, interviews and session recordings
To be addedConsensus statements and practice guidance
To be addedPresentation decks for education and advocacy
To be addedOrganisations and institutional partners will be featured here following confirmation and permission to publish.
If your organisation is working on detection, access, integrated care or capability in metabolic health, we would like to hear from you.
Start a conversation
